Effects of Nicergoline on Age-Related Decrements in Radial Maze Performance and Acetylcholine Levels

McArthur, Robert A.; Carfagna, Nicola; Banfi, Laura; Cavanus, S.; Cervini, M. A.; Fariello, Ruggero G.; Post, Claes

doi:10.1016/s0361-9230(97)00010-5

Cited by 26 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the dopaminergic D1-receptor was antagonized with SCH 23390. Both adrenergic antagonists (Caraci et al 2005;Nagoshi et al 2015) and age-related cognitive decline (McArthur et al 1997;Pereira et al 2014). Riluzole and propranolol aid fear extinction in animal models (Fitzgerald et al 2015;Sugiyama et al 2015), and are being investigated as potential treatments for human anxiety disorders (Pittenger et al 2008;Nandhra et al 2013).…”

Section: Catecholaminesmentioning

confidence: 99%

Neurotransmitter signaling pathways required for normal development inXenopus laevisembryos: a pharmacological survey screen

Sullivan

Levin

2016

Journal of Anatomy

View full text Add to dashboard Cite

Neurotransmitters are not only involved in brain function but are also important signaling molecules for many diverse cell types. Neurotransmitters are widely conserved, from evolutionarily ancient organisms lacking nervous systems through man. Here, we report results from a loss- and gain-of-function survey, using pharmacologic modulators of several neurotransmitter pathways to examine possible roles in normal embryogenesis. Applying reagents targeting the glutamatergic, adrenergic, and dopaminergic pathways to embryos of Xenopus laevis from gastrulation to organogenesis stages, we observed and quantified numerous malformations including craniofacial defects, hyperpigmentation, muscle mispatterning, and miscoiling of the gut. These data implicate several key neurotransmitters in new embryonic patterning roles, reveal novel earlier stages for processes involved in eye development, suggest new targets for subsequent molecular-genetic investigation, and highlight the necessity for in-depth toxicology studies of psychoactive compounds to which human embryos might be exposed during pregnancy.

show abstract

Section: Catecholaminesmentioning

confidence: 99%

Neurotransmitter signaling pathways required for normal development inXenopus laevisembryos: a pharmacological survey screen

Sullivan

Levin

2016

Journal of Anatomy

View full text Add to dashboard Cite

show abstract

“…As an alpha α1‐adrenoceptor antagonist, nicergoline may have caused vasodilation, which in turn improved cerebral circulation . Nicergoline has been shown to stimulate cholinergic neurotransmission, a system that has been attributed to the pathology of AD, both by increasing acetylcholine release from cholinergic nerve terminals and by inhibiting its degradation . Moreover, nicergoline may exert a positive effect on the neuronal signal transduction system by stimulating the phosphoinositide pathway, which has been reported to be impaired in AD .…”

Section: Discussionmentioning

confidence: 99%

“…28,29 Nicergoline has been shown to stimulate cholinergic neurotransmission, a system that has been attributed to the pathology of AD, both by increasing acetylcholine release from cholinergic nerve terminals and by inhibiting its degradation. 5,[30][31][32][33] Moreover, nicergoline may exert a positive effect on the neuronal signal transduction system by stimulating the phosphoinositide pathway, which has been reported to be impaired in AD. 29 Nicergoline may also increase protein kinase C (PKC) translocation, which combats beta-amyloid deposition, and slow down the reduction of nerve growth factor, which may help in preventing cholinergic neuron loss.…”

Section: Discussionmentioning

confidence: 99%

Effects of nicergoline treatment on regional cerebral blood flow in early Alzheimer's disease

Jeong

et al. 2019

Int J Imaging Syst Tech

View full text Add to dashboard Cite

Alzheimer's disease (AD) is associated with reduction of regional cerebral blood flow (rCBF) in various brain regions. Although nicergoline has been used to treat cognitive impairment in various types of dementia, the effect of nicergoline on brain perfusion in AD has not been elucidated. The aim of the study was to examine the effect of nicergoline on rCBF in patients with early AD using technetium‐99m hexamethylpropylene amine oxime single‐photon emission computed tomography (SPECT). For 1.7 years on average, 22 patients with early AD received nicergoline (30 mg twice daily) and acetylcholinesterase inhibitors (AChEI), whereas other 22 patients received AChEI only. All patients underwent assessment of dementia severity and SPECT scans at baseline and follow‐up. We compared baseline rCBF and annual percent change of rCBF between the two groups. There were no significant differences in rCBF between the groups at baseline. Although changes in dementia severity was not statistically different, the annual percent changes of rCBF were higher in the left temporal pole (−0.12 ± 3.95 vs −3.38 ± 3.30, P = 0.002) and middle cingulate gyrus (1.91 ± 3.58 vs −1.34 ± 3.17, P = 0.002) among the nicergoline group. Our study demonstrated that nicergoline treatment combined with AChEI either better preserves or further improves cerebral perfusion in the temporal and cingulate cortices in patients with early AD compared to AChEI treatment alone. These results may indicate potential beneficial effects of nicergoline on brain functions in AD.

show abstract

“…4 Dement These biochemical effects of nicergoline have behav ioral correlates in animals. McArthur et al [9] found that nicergoline significantly improved the poor performance of aged rats in a radial-arm maze test of memory ( fig. 2).…”

Section: ]mentioning

confidence: 99%

“…Nicergoline increases the levels of acetylcholine in the cortex and striatum of old rats, without affecting levels in young rats [9], and also restores the age-related decline in hippocampal acetylcholine release in rats [10], In addi tion, nicergoline has an antagonistic effect on both norad renergic di-receptors and serotonergic 5-HTiA receptors [ …”

Section: Treatment For Dementiamentioning

confidence: 99%

Altered Neurotransmission and Signal Transduction: Targets for Nicergoline Treatment

Winblad

1997

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Effects of Nicergoline on Age-Related Decrements in Radial Maze Performance and Acetylcholine Levels

Cited by 26 publications

References 34 publications

Neurotransmitter signaling pathways required for normal development inXenopus laevisembryos: a pharmacological survey screen

Neurotransmitter signaling pathways required for normal development inXenopus laevisembryos: a pharmacological survey screen

Effects of nicergoline treatment on regional cerebral blood flow in early Alzheimer's disease

Altered Neurotransmission and Signal Transduction: Targets for Nicergoline Treatment

Contact Info

Product

Resources

About